BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-1 antibody tislelizumab, its investigational BTK inhibitor zanubrutinib, and its investigational PARP inhibitor pamiparib, will be presented in seven oral presentations and four poster presentations at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China.

Oral Presentations:

Title:Tislelizumab in Chinese Patients with Non-Small Cell Lung
Cancer (NSCLC) and Nasopharyngeal Carcinoma (NPC)
Session:Lung Cancer Session 1
Date:Thursday, September 19
Time:11:20 – 11:25
LocationAuditorium, Level 1
PresenterQing Zhou, M.D., Ph.D., Guangdong Provincial People’s Hospital


Title:Tislelizumab for Relapsed/Refractory Classical Hodgkin
Lymphoma: Updated Follow-up Efficacy and Safety Results
from a Phase 2 Study
Session:Innovative Drug Clinical Data Session 1
Date:Thursday, September 19
Time:14:30 – 14:40
LocationStrait Hall, Level 2
Presenter:Yuqin Song, M.D., Ph.D., Beijing Cancer Hospital


Title:Tislelizumab in Chinese Patients with Melanoma, Urothelial
Carcinoma (UC), and Renal Cell Carcinoma (RCC)
Session:Kidney Cancer Session 4
Date:Thursday, September 19
Time:16:35 – 16:40
LocationConference Room 2A, Level 2
Presenter:Lili Mao, M.D., Ph.D. Beijing Cancer Hospital


Title:Tislelizumab in Chinese Patients with Esophageal Cancer
(EC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC),
and Microsatellite Instability-High/Mismatch Repair Deficient
(MSI-H/dMMR) Tumors
Session:Advanced Gastric Cancer Session 3
Date:Friday, September 20
Time:11:24 – 11:36
LocationBanquet Hall 1, Level 2
Presenter:Lin Shen, M.D., Ph.D., Beijing Cancer Hospital


Title:Safety and Efficacy in Patients with Long-Term Exposure 
(LTE) to Tislelizumab, an Investigational Anti-PD-1 Antibody,
in a First-in-Human Phase 1 Study
Session:Immuno-Oncology Session 3
Date:Friday, September 20
Time:11:54 – 12:00
LocationHall 1G, Level 1
PresenterChia-Jui Yen, M.D., Ph.D., National Cheng Kung University Hospital


Title:Tislelizumab Plus Chemotherapy as First-Line Treatment for
Chinese Patients with Lung Cancer
Session:Lung Cancer Session 3
Date:Saturday, September 21
Time:11:38 – 11:44
LocationAuditorium, Level 1
Presenter:Zhijie Wang, M.D., Ph.D., Cancer Hospital, Chinese Academy of Medical Sciences


Title:Tislelizumab in Combination with Chemotherapy as
Treatment for Chinese Patients with Esophageal Squamous
Cell Carcinoma (ESCC)
Session:Innovative Drug Clinical Data Session 1
Date:Saturday, September 21
Time:14:30 – 14:40
LocationBanquet Hall 2, Level 2
Presenter:Ru Jia, M.D., The Fifth Medical Center, General Hospital of the People’s Liberation Army
  

Poster Presentations:

Title:Dose Escalation of Pamiparib in Chinese Patients with High-
Grade Non-Mucinous Ovarian Cancer (HGOC) or Advanced
Triple-Negative Breast Cancer (TNBC)
Board #:P-36
Date:Thursday, September 19
Time:Afternoon
Location:Strait Hall Poster Area, Level 2
Presenter:Xiyan Mu, M.D., BeiGene


Title:Zanubrutinib for Patients with Relapsed or Refractory
Chronic Lymphocytic Leukemia or Small Lymphocytic
Lymphoma
Board #:P-45
Date:Friday, September 20
Time:Morning
Location:Strait Hall Poster Area, Level 2
Presenter:Meng Ji, M.D., BeiGene


Title:Zanubrutinib, a Highly Specific BTK Inhibitor in Chinese
Patients with Relapsed/Refractory B-cell Malignancies:
Follow-up Report of a Phase 1 Trial in China
Board #:P-46
Date:Friday, September 20
Time:Morning
Location:Strait Hall Poster Area, Level 2
Presenter:Chenmu Du, M.D., BeiGene


Title:The molecular binding mechanism of tislelizumab, an
investigational anti-PD-1 antibody, is differentiated from
pembrolizumab and nivolumab
Board #:P-60
Date:Friday, September 20
Time:Morning
Location:Strait Hall Poster Area, Level 2
Presenter:Ye Liu, Ph.D., BeiGene

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1

Investor Contact Media Contact
Craig WestLiza Heapes
+1 857-302-5189+1 857-302-5663
ir@beigene.commedia@beigene.com


 __________________________________
1 ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.